Policy paper
G7 Finance Ministers’ Statement on Actions to Support Antibiotic Development
G7 Finance Ministers have today (13 December 2021) agreed a G7 statement on Actions to Support Antibiotic Development, aiming to strengthen G7 preparedness against the “silent pandemic” of antimicrobial resistance.
This was published under the 2019 to 2022 Johnson Conservative government
Documents
PDF, 261 KB, 1 page
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
digital.communications@hmtreasury.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 626 KB, 5 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
digital.communications@hmtreasury.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 367 KB, 3 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
digital.communications@hmtreasury.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
All G7 members recognise antimicrobial resistance (AMR) as requiring a multi-year and multi-stakeholder effort.
All G7 members have committed to expedite the implementation of their existing AMR Action Plans and related strategies, and to take additional specific and appropriate steps to address antibiotic market failure and create the right economic conditions to preserve essential existing antibiotics and ensure their access, strengthen AMR antibiotic research and development, and bring new drugs to market where they meet identified public health needs.
See the Annex for examples of G7 action.
Updates to this page
Published 13 December 2021